Home >> Research Area >>Microbiology and Virology>>Antibiotic>> Delafloxacin meglumine

Delafloxacin meglumine

Fluoroquinolone antibiotic agent CAS# 352458-37-8

Delafloxacin meglumine

Catalog No. BCC1523----Order now to get a substantial discount!

Product Name & Size Price Stock
Delafloxacin meglumine: 5mg $299 In Stock
Delafloxacin meglumine: 10mg Please Inquire In Stock
Delafloxacin meglumine: 20mg Please Inquire Please Inquire
Delafloxacin meglumine: 50mg Please Inquire Please Inquire
Delafloxacin meglumine: 100mg Please Inquire Please Inquire
Delafloxacin meglumine: 200mg Please Inquire Please Inquire
Delafloxacin meglumine: 500mg Please Inquire Please Inquire
Delafloxacin meglumine: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Delafloxacin meglumine

Number of papers citing our products

Chemical structure

Delafloxacin meglumine

3D structure

Chemical Properties of Delafloxacin meglumine

Cas No. 352458-37-8 SDF Download SDF
PubChem ID 11578213 Appearance Powder
Formula C25H29ClF3N5O9 M.Wt 635.97
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble in DMSO
Chemical Name 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid;(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol
SMILES CNCC(C(C(C(CO)O)O)O)O.C1C(CN1C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4=NC(=C(C=C4F)F)N)F)O
Standard InChIKey AHJGUEMIZPMAMR-WZTVWXICSA-N
Standard InChI InChI=1S/C18H12ClF3N4O4.C7H17NO5/c19-12-13-7(1-9(20)14(12)25-3-6(27)4-25)15(28)8(18(29)30)5-26(13)17-11(22)2-10(21)16(23)24-17;1-8-2-4(10)6(12)7(13)5(11)3-9/h1-2,5-6,27H,3-4H2,(H2,23,24)(H,29,30);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Delafloxacin meglumine Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Delafloxacin meglumine Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Delafloxacin meglumine

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.5724 mL 7.862 mL 15.724 mL 31.448 mL 39.31 mL
5 mM 0.3145 mL 1.5724 mL 3.1448 mL 6.2896 mL 7.862 mL
10 mM 0.1572 mL 0.7862 mL 1.5724 mL 3.1448 mL 3.931 mL
50 mM 0.0314 mL 0.1572 mL 0.3145 mL 0.629 mL 0.7862 mL
100 mM 0.0157 mL 0.0786 mL 0.1572 mL 0.3145 mL 0.3931 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Delafloxacin meglumine

Description: IC50 Value: MICs ranging from 0.0078 to 0.125 micro g/ml for levofloxacin-resistant Streptococcus pneumoniae strains [1] ABT-492 was more potent against quinolone-susceptible and -resistant gram-positive organisms, had activity similar to that of ciprofloxacin against certain members of the family Enterobacteriaceae, and had comparable activity against quinolone-susceptible, nonfermentative, gram-negative organisms. in vitro: ABT-492 exhibited excellent in vitro activities against all 326 aerobic and anaerobic antral puncture sinus isolates tested with MICs (in micrograms per milliliter) at which 90% of the isolates tested were inhibited as follows: Haemophilus influenzae, 0.001; Moraxella catarrhalis, 0.008; and Streptococcus pneumoniae, 0.015 [2]. ABT-492 was as active as trovafloxacin against Chlamydia trachomatis, indicating good intracellular penetration and antibacterial activity [3]. in vivo: N/A Clinical trial: N/A

Featured Products
New Products
 

References on Delafloxacin meglumine

Delafloxacin meglumine for the treatment of acute bacterial skin and skin structure infections (ABSSSI).[Pubmed:30539165]

Drugs Today (Barc). 2018 Nov;54(11):657-666.

Delafloxacin meglumine (Baxdela, WQ-3034, ABT-492, RX-3341; Melinta Therapeutics) was approved by the U.S. Food and Drug Administration (FDA) in June 2017 for the treatment of acute bacterial skin and skin structure infections on the basis of data from two phase III trials. Delafloxacin is a broad-spectrum anionic fluoroquinolone and its distinct chemical structure increases its potency in acidic environments. It is known to inhibit DNA replication and repair by targeting DNA gyrase and topoisomerase IV. Delafloxacin is administered via both oral and parenteral routes. It has potent activity against methicillin-resistant Staphylococcus aureus and Streptococci, and is also effective against Enterobacteriaceae and Pseudomonas aeruginosa. Delafloxacin is currently in phase III evaluation for treatment of community-acquired pneumonia and was classified as a qualified infectious disease product by the U.S. FDA in its approval.

Keywords:

Delafloxacin meglumine,352458-37-8,Natural Products,Antibiotic, buy Delafloxacin meglumine , Delafloxacin meglumine supplier , purchase Delafloxacin meglumine , Delafloxacin meglumine cost , Delafloxacin meglumine manufacturer , order Delafloxacin meglumine , high purity Delafloxacin meglumine

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: